Reported about 5 hours ago
Shares of Kenvue, the maker of Tylenol, rebounded sharply before the market opened on Tuesday, following a significant drop after President Trump made unfounded claims linking Tylenol to autism during a news conference. Despite Trump’s warnings to pregnant women against using the medication, Kenvue refuted any connection to autism and emphasized the risks of not using the drug when needed. Analysts anticipate a positive market response for Kenvue, especially given the absence of new scientific evidence against the product.
Source: YAHOO